A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells.
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
/ metabolism
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Culture Techniques
/ methods
Cell Differentiation
/ drug effects
Cell Line
Cell Line, Tumor
Cell Movement
/ drug effects
Coculture Techniques
/ methods
Docetaxel
/ pharmacology
Fibroblasts
/ cytology
Humans
Keratinocytes
/ cytology
Melanoma
/ metabolism
Spheroids, Cellular
/ cytology
3D in vitro model
ABCB5
HaCaT
Melanoma
SK-MEL-28
Spheroid
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Apr 2019
29 Apr 2019
Historique:
received:
25
10
2018
accepted:
12
04
2019
entrez:
1
5
2019
pubmed:
1
5
2019
medline:
27
8
2019
Statut:
epublish
Résumé
Different 3D-cell culture approaches with varying degrees of complexity have been developed to serve as melanoma models for drug testing or mechanistic studies. While these 3D-culture initiatives are already often superior to classical 2D approaches, they are either composed of only melanoma cells or they are so complex that the behavior of individual cell types is hard to understand, and often they are difficult to establish and expensive. This study used low-attachment based generation of spheroids composed of up to three cell types. Characterization of cells and spheroids involved cryosectioning, immunofluorescence, FACS, and quantitative analyses. Statistical evaluation used one-way ANOVA with post-hoc Tukey test or Student's t-test. The tri-culture model allowed to track cellular behavior in a cell-type specific manner and recapitulated different characteristics of early melanoma stages. Cells arranged into a collagen-IV rich fibroblast core, a ring of keratinocytes, and groups of highly proliferating melanoma cells on the outside. Regularly, some melanoma cells were also found to invade the fibroblast core. In the absence of melanoma cells, the keratinocyte ring stratified into central basal-like and peripheral, more differentiated cells. Conversely, keratinocyte differentiation was clearly reduced upon addition of melanoma cells. Treatment with the cytostatic drug, docetaxel, restored keratinocyte differentiation and induced apoptosis of external melanoma cells. Remaining intact external melanoma cells showed a significantly increased amount of ABCB5-immunoreactivity. In the present work, a novel, simple spheroid-based melanoma tri-culture model composed of fibroblasts, keratinocytes, and melanoma cells was described. This model mimicked features observed in early melanoma stages, including loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced increase of ABCB5 expression in external melanoma cells.
Sections du résumé
BACKGROUND
BACKGROUND
Different 3D-cell culture approaches with varying degrees of complexity have been developed to serve as melanoma models for drug testing or mechanistic studies. While these 3D-culture initiatives are already often superior to classical 2D approaches, they are either composed of only melanoma cells or they are so complex that the behavior of individual cell types is hard to understand, and often they are difficult to establish and expensive.
METHODS
METHODS
This study used low-attachment based generation of spheroids composed of up to three cell types. Characterization of cells and spheroids involved cryosectioning, immunofluorescence, FACS, and quantitative analyses. Statistical evaluation used one-way ANOVA with post-hoc Tukey test or Student's t-test.
RESULTS
RESULTS
The tri-culture model allowed to track cellular behavior in a cell-type specific manner and recapitulated different characteristics of early melanoma stages. Cells arranged into a collagen-IV rich fibroblast core, a ring of keratinocytes, and groups of highly proliferating melanoma cells on the outside. Regularly, some melanoma cells were also found to invade the fibroblast core. In the absence of melanoma cells, the keratinocyte ring stratified into central basal-like and peripheral, more differentiated cells. Conversely, keratinocyte differentiation was clearly reduced upon addition of melanoma cells. Treatment with the cytostatic drug, docetaxel, restored keratinocyte differentiation and induced apoptosis of external melanoma cells. Remaining intact external melanoma cells showed a significantly increased amount of ABCB5-immunoreactivity.
CONCLUSIONS
CONCLUSIONS
In the present work, a novel, simple spheroid-based melanoma tri-culture model composed of fibroblasts, keratinocytes, and melanoma cells was described. This model mimicked features observed in early melanoma stages, including loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced increase of ABCB5 expression in external melanoma cells.
Identifiants
pubmed: 31035967
doi: 10.1186/s12885-019-5606-4
pii: 10.1186/s12885-019-5606-4
pmc: PMC6489189
doi:
Substances chimiques
ABCB5 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Langues
eng
Pagination
402Subventions
Organisme : Bundesministerium für Bildung und Forschung (DE)
ID : 03FH8I01IA
Organisme : Bundesministerium für Bildung und Forschung (DE)
ID : M2OLIE
Références
Acta Oncol. 1999;38(5):535-47
pubmed: 10427941
Am J Pathol. 2000 Jan;156(1):193-200
pubmed: 10623667
Proc Natl Acad Sci U S A. 1976 Sep;73(9):3278-82
pubmed: 1067619
Int J Cancer. 2001 Sep 1;93(5):617-22
pubmed: 11477569
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Clin Cancer Res. 2002 Dec;8(12):3728-33
pubmed: 12473582
J Biol Chem. 2003 Nov 21;278(47):47156-65
pubmed: 12960149
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Cancer Res. 2004 Jun 15;64(12):4294-301
pubmed: 15205344
Cancer Cell. 2004 Aug;6(2):129-37
pubmed: 15324696
J Cell Physiol. 2005 Aug;204(2):522-31
pubmed: 15744745
Pigment Cell Res. 2005 Apr;18(2):102-12
pubmed: 15760339
Cancer Res. 2005 May 15;65(10):4320-33
pubmed: 15899824
J Natl Cancer Inst. 1991 Feb 20;83(4):288-91
pubmed: 1671606
Mol Cancer Ther. 2006 May;5(5):1136-44
pubmed: 16731745
Mol Cancer Ther. 2007 Feb;6(2):752-61
pubmed: 17308071
Nature. 2008 Jan 17;451(7176):345-9
pubmed: 18202660
Cytotechnology. 2007 Jun;54(2):77-83
pubmed: 19003021
Skin Pharmacol Physiol. 2009;22(2):114-21
pubmed: 19188759
J Am Acad Dermatol. 2009 May;60(5):719-35; quiz 736-8
pubmed: 19389517
Facial Plast Surg Clin North Am. 2009 Aug;17(3):337-48
pubmed: 19698915
Science. 2010 Jun 25;328(5986):1662-8
pubmed: 20576885
Pigment Cell Melanoma Res. 2010 Dec;23(6):820-7
pubmed: 20973932
Ann Intern Med. 2010 Nov 2;153(9):587-91
pubmed: 21041578
Expert Rev Anticancer Ther. 2010 Nov;10(11):1811-23
pubmed: 21080806
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Cancer Chemother Pharmacol. 2011 Oct;68(4):1081-7
pubmed: 21769667
Genes Dev. 2012 Jun 1;26(11):1131-55
pubmed: 22661227
PLoS One. 2012;7(5):e36762
pubmed: 22675422
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Expert Opin Drug Discov. 2008 Jan;3(1):1-10
pubmed: 23480136
Ann N Y Acad Sci. 2013 Jul;1291:1-13
pubmed: 23772560
Cell Death Dis. 2013 Jul 11;4:e719
pubmed: 23846221
PLoS One. 2013 Oct 07;8(10):e77507
pubmed: 24116231
Methods Mol Biol. 2014;1195:33-41
pubmed: 24155234
Curr Treat Options Oncol. 2014 Jun;15(2):321-35
pubmed: 24599525
Cancer Res. 2014 Aug 1;74(15):4196-207
pubmed: 24934811
Nat Biotechnol. 2014 Aug;32(8):760-72
pubmed: 25093883
Lab Chip. 2015 Feb 7;15(3):882-8
pubmed: 25490891
Mol Cancer. 2015 Jan 05;14:1
pubmed: 25560632
J Cancer Res Clin Oncol. 2015 May;141(5):951-9
pubmed: 25773123
J Control Release. 2015 Dec 28;220(Pt A):503-514
pubmed: 26578440
Adv Healthc Mater. 2016 Apr 20;5(8):936-46
pubmed: 26890862
Healthcare (Basel). 2013 Dec 23;2(1):27-46
pubmed: 27429258
Clin Exp Dermatol. 2016 Oct;41(7):709-16
pubmed: 27663144
Cancer Metastasis Rev. 2017 Mar;36(1):7-21
pubmed: 28321632
Stem Cell Rev. 2017 Jun;13(3):418-429
pubmed: 28536890
Nanotechnology. 2017 Jul 21;28(29):295103
pubmed: 28574851
Semin Cell Dev Biol. 2018 Jun;78:73-84
pubmed: 28676423
PeerJ. 2017 Sep 5;5:e3754
pubmed: 28890854
Anticancer Res. 2018 Apr;38(4):2101-2108
pubmed: 29599328
Exp Dermatol. 2018 May;27(5):578-586
pubmed: 29697862
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
J Cancer Res Clin Oncol. 2018 Dec;144(12):2283-2302
pubmed: 30094536
J Control Release. 2018 Sep 28;286:369-380
pubmed: 30096401
Drugs. 2018 Aug;78(12):1197-1209
pubmed: 30097888
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
Recent Results Cancer Res. 1995;139:57-67
pubmed: 7597312
Semin Oncol. 1975 Jun;2(2):83-103
pubmed: 790575
J Invest Dermatol. 1993 Mar;100(3):342S-345S
pubmed: 8440920